Literature DB >> 2115457

Immunological involvement in the efficacy of praziquantel.

P J Brindley1, A Sher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2115457     DOI： 10.1016/0014-4894(90)90028-b

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN： 0014-4894            Impact factor:   2.011


× No keyword cloud information.
  10 in total

1.  Interleukin 5 (IL-5) is not required for expression of a Th2 response or host resistance mechanisms during murine schistosomiasis mansoni but does play a role in development of IL-4-producing non-T, non-B cells.

Authors:  L R Brunet; E A Sabin; A W Cheever; M A Kopf; E J Pearce
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

Review 2.  Ca²⁺ channels and praziquantel: a view from the free world.

Authors:  John D Chan; Magdalena Zarowiecki; Jonathan S Marchant
Journal:  Parasitol Int       Date:  2012-12-16       Impact factor: 2.230

3.  Hepatic schistosomiasis.

Authors:  Karin L Andersson; Raymond T Chung
Journal:  Curr Treat Options Gastroenterol       Date:  2007-12

Review 4.  The Journey to Discovering a Flatworm Target of Praziquantel: A Long TRP.

Authors:  Sang-Kyu Park; Jonathan S Marchant
Journal:  Trends Parasitol       Date:  2019-11-29

5.  A paragonimiasis patient with allergic reaction to praziquantel and resistance to triclabendazole: successful treatment after desensitization to praziquantel.

Authors:  Sun Young Kyung; Yong Kyun Cho; Yu Jin Kim; Jeong-Woong Park; Sung Hwan Jeong; Jae-Ik Lee; Yon Mi Sung; Sang Pyo Lee
Journal:  Korean J Parasitol       Date:  2011-03-18       Impact factor: 1.341

6.  Praziquantel decreases fecundity in Schistosoma mansoni adult worms that survive treatment: evidence from a laboratory life-history trade-offs selection study.

Authors:  Poppy H L Lamberton; Christina L Faust; Joanne P Webster
Journal:  Infect Dis Poverty       Date:  2017-06-16       Impact factor: 4.520

7.  Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo-controlled trial.

Authors:  Robert Tweyongyere; Patrice A Mawa; Sophy Ngom-Wegi; Juliet Ndibazza; Trinh Duong; Birgitte J Vennervald; David W Dunne; Eli Katunguka-Rwakishaya; Alison M Elliott
Journal:  J Infect Dis       Date:  2008-12-15       Impact factor: 5.226

8.  Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo-controlled trial.

Authors:  Robert Tweyongyere; Patrice A Mawa; Nicholas O Emojong; Harriet Mpairwe; Frances M Jones; Trinh Duong; David W Dunne; Birgitte J Vennervald; Eli Katunguka-Rwakishaya; Alison M Elliott
Journal:  BMC Infect Dis       Date:  2009-03-18       Impact factor: 3.090

9.  New approaches to measuring anthelminthic drug efficacy: parasitological responses of childhood schistosome infections to treatment with praziquantel.

Authors:  Martin Walker; Tarub S Mabud; Piero L Olliaro; Jean T Coulibaly; Charles H King; Giovanna Raso; Alexandra U Scherrer; J Russell Stothard; José Carlos Sousa-Figueiredo; Katarina Stete; Jürg Utzinger; Maria-Gloria Basáñez
Journal:  Parasit Vectors       Date:  2016-01-27       Impact factor: 3.876

10.  The anthelmintic drug praziquantel activates a schistosome transient receptor potential channel.

Authors:  Sang-Kyu Park; Gihan S Gunaratne; Evgeny G Chulkov; Francie Moehring; Paul McCusker; Peter I Dosa; John D Chan; Cheryl L Stucky; Jonathan S Marchant
Journal:  J Biol Chem       Date:  2019-10-25       Impact factor: 5.157
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.